Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient


Lucio Iannone, Ph.D.

Board Director

Lucio Iannone is VP of Venture Investments Health at Leaps by Bayer. He is responsible for leading the investment team in the USA and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science.

As an investor, Lucio also serves as board member for AffiniT, Khloris Biosciences, Immunitas Therapeutics, Mozart Tx and Paratus. Before joining Leaps by Bayer, he had different roles in biotechnology companies. He has experience with molecular biology, cell and gene therapy technologies and their application in oncology, cardiovascular and other therapeutic fields.

Lucio obtained his Ph.D. in Medicine at the Imperial College of London.

211110C LEAPS IANNONE 0443